Response and biological subtype of myeloma are independent prognostic factors and combine to define outcome after high-dose therapy.

about

The impact of intra-clonal heterogeneity on the treatment of multiple myeloma.

P2860

Q38192044-5C4D5996-6215-45B3-AA13-F3F9E3C36CA9

P2860

Response and biological subtype of myeloma are independent prognostic factors and combine to define outcome after high-dose therapy.

Item

http://www.wikidata.org/entity/Q53122662

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Response and biological subtyp ...... tcome after high-dose therapy.

@en

Response and biological subtyp ...... tcome after high-dose therapy.

@nl

type

Item

label

Response and biological subtyp ...... tcome after high-dose therapy.

@en

Response and biological subtyp ...... tcome after high-dose therapy.

@nl

prefLabel

Response and biological subtyp ...... tcome after high-dose therapy.

@en

Response and biological subtyp ...... tcome after high-dose therapy.

@nl

P1476

Response and biological subtyp ...... utcome after high-dose therapy

@en

P2093

Faith E Davies

http://www.w3.org/2001/XMLSchema#string

Fiona M Ross

http://www.w3.org/2001/XMLSchema#string

Graham H Jackson

http://www.w3.org/2001/XMLSchema#string

Martin F Kaiser

http://www.w3.org/2001/XMLSchema#string

Ping Wu

http://www.w3.org/2001/XMLSchema#string

Roger Owen

http://www.w3.org/2001/XMLSchema#string

Walter M Gregory

http://www.w3.org/2001/XMLSchema#string

P2860

International uniform response criteria for multiple myeloma.

Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation.

A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial.

Long-term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high-dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments.

A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study

Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du M

Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma

P304

291-294

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BJH.12218

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

161

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-01-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235377969

http://www.w3.org/2001/XMLSchema#string

P698

23356460

http://www.w3.org/2001/XMLSchema#string

Response and biological subtype of myeloma are independent prognostic factors and combine to define outcome after high-dose therapy.

about

P2860

P2860

Response and biological subtype of myeloma are independent prognostic factors and combine to define outcome after high-dose therapy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698